Rani Total Cash From Financing Activities from 2010 to 2025

RANI Stock  USD 1.31  0.01  0.76%   
Rani Therapeutics' Total Cash From Financing Activities is increasing with slightly volatile movements from year to year. Total Cash From Financing Activities is predicted to flatten to about 199.2 K. For the period between 2010 and 2025, Rani Therapeutics, Total Cash From Financing Activities quarterly trend regression had mean deviation of  17,947,994 and range of 76.9 M. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
2010-12-31
Previous Quarter
209.7 K
Current Value
199.2 K
Quarterly Volatility
25.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 4.2 M, Depreciation And Amortization of 925.5 K or Interest Expense of 6.1 M, as well as many indicators such as Price To Sales Ratio of 130, Dividend Yield of 0.0 or PTB Ratio of 6.22. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Rani Therapeutics Correlation against competitors.

Latest Rani Therapeutics' Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Rani Therapeutics Holdings over the last few years. It is Rani Therapeutics' Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rani Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Slightly volatile
   Total Cash From Financing Activities   
       Timeline  

Rani Total Cash From Financing Activities Regression Statistics

Arithmetic Mean11,749,682
Geometric Mean1,433,814
Coefficient Of Variation218.36
Mean Deviation17,947,994
Median852,000
Standard Deviation25,656,688
Sample Variance658.3T
Range76.9M
R-Value0.31
Mean Square Error639.2T
R-Squared0.09
Significance0.25
Slope1,649,462
Total Sum of Squares9874T

Rani Total Cash From Financing Activities History

2025199.2 K
2024209.7 K
2023233 K
202229 M
202177.1 M
202072.7 M

About Rani Therapeutics Financial Statements

Investors use fundamental indicators, such as Rani Therapeutics' Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Although Rani Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Cash From Financing Activities209.7 K199.2 K

Currently Active Assets on Macroaxis

When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:
Check out the analysis of Rani Therapeutics Correlation against competitors.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.04)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.57)
Return On Equity
(2.25)
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.